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which in turn has translated to improved progression-free
and overall survival. Their results underscore the impor-
tance of designing prospective trials to better deﬁne the role
of allogeneic transplant in myeloma, speciﬁcally the patient
population that might beneﬁt and the conditioning approach
that is most appropriate.ACKNOWLEDGMENTS
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a large number of publications have reported a strong asso-
ciation between elevated serum ferritin before allogeneic
hematopoietic stem cell transplantation (HSCT) and
decreased post-HSCT overall survival (OS). Although this
association is now beyond doubt, many areas of uncertainty
remain.
In this context, the study of Dr. Meyer and colleagues [2]
in this issue of Biology of Blood and Marrow Transplantation
adds both light and darkness. They report the dynamic
behavior of serum iron parameters, most notably ferritin,
among 290 patients who underwent myeloablative HSCT at
their center. As previously described, ferritin levels increasedin the few months after transplantation and then decreased
to below pre-HSCT levels in long-term survivors. They also
could conﬁrm that pre-HSCT ferritin is associated with
increased nonrelapse mortality (NRM) and decreased OS.
However, the most important ﬁnding of this study is that an
elevated ferritin was associated with increased mortality
even in 6-, 12-, and 24-month landmark analyses. This effect
appeared to depend on both an increased risk of relapse and
an increased risk of NRM in patients with elevated ferritin.
Thisﬁnding can be interpreted in at least three differentways.
First, it is possible that iron overload is indeed detri-
mental after HSCT, as previously assumed based on ferritin
studies and for the reasons previously adduced: increased
risk of infection, especially fungal, and liver toxicity. The
present study would suggest that this effect extends to long-
term survivors of HSCT. However, this seems the least likely
explanation. Indeed, long-termmortality after HSCT depends
primarily on disease relapse and complications of chronic
graft-versus-host disease (GVHD), not liver toxicity (which is
a very rare cause of death after the early post-HSCT period)
or fungal infection (outside of the context of chronic
GVHD and immunosuppression). There has been little
evidence to date that hyperferritinemia is associated with
the subsequent development of chronic GVHD. In Dr. Meyer’s
study, the adverse effect of hyperferritinemia on long-term
survivors was primarily due to relapse, not NRM, which is
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based on nearly all published studies on the topic, including
the present one, is driven primarily by an increase in NRM).
The second interpretation would be that iron overload
exerts inﬂuences that are not limited to those commonly
suspected and that its effect is modulated by the clinical
context. Early after HSCT, with the myeloablative
conditioning-induced rise in labile plasma iron, the major
toxicities would relate to infection and liver toxicity, which
may dependmore on labile than parenchymal iron. Late after
HSCT, when iron overload may be associated with less labile
iron elevation, iron overload could modulate antitumor
immunity or directly impact tumor growth. Indeed, there are
now anecdotal reports that iron chelation may be associated
with antitumor activity, consistent with an interaction
between iron homeostasis and tumor growth.
Third, it may be that the effect of hyperferritinemia has
little to do with iron overload. Despite the widespread
assumption that our knowledge of hyperferritinemia can be
directly translated to iron overload (witness the ﬁrst sen-
tence of Dr. Meyer’s abstract), this fact has not yet been
proven. Ferritin is undeniably strongly correlated with iron
burden, with a correlation coefﬁcient between it and liver
iron content reported to be around 0.6 to 0.75. This means,
however, that one half to two thirds of the variance in ferritin
values depends on factors other than iron burden, including
inﬂammatory issues, which we know to be prognostically
relevant in HSCT [3].
Three recent HSCT studies have examined the prognostic
importance of iron overload as determined by magnetic
resonance imagingequantiﬁed liver iron content, which
presumably is a better reﬂection of iron burden than ferritin.
Two of the studies found no association of liver iron content
with NRM or OS, whereas one did [4-6]. Therefore, at this
time the question remains: is iron overload truly associated
with increased post-HSCT mortality? And if not, what does
hyperferritinemia mean?
The most pedestrian explanation of much of the ferritin
literature is that it simply reﬂects ferritin’s role as amarker of
acute phase/inﬂammatory issues, caused by tumor, organ
toxicity, and GVHD, which are all going to be strongly tied to
HSCT outcome. Our ability to adjust for this, by including in
the multivariable models other acute phase reactants,
markers of disease risk such as the European Group for Bloodand Marrow Transplantation risk score, or covariates for the
occurrence of GVHD (as done by Dr. Meyer and colleagues), is
commendable but limited because we do not have very good
tools to account for organ injury, infection, disease relapse
risk, or GVHD severity. The possibility of confounding by any
of these remains strong.
Howwill we resolve this question? At this point, we likely
have drawn dry the well of ferritin-based knowledge. We
now need more and larger studies that incorporate direct
measurements of parenchymal and labile iron. Only through
those will we be able to provide deﬁnitive answers regarding
the role of iron overload in HSCT. In the words of Tennyson, it
may be that the gulfs will wash us down, and that we will
ﬁnd very little effect of iron overload in HSCTand put the iron
issue to rest. Or it may be that we shall touch the Happy Isles
and learn about simple and complex ways through which
iron overload impacts transplant toxicity and tumor growth.
Then, and perhaps only then, canwe take the next challenge:
to learn how to use chelation strategies pre- and post-HSCT
to mitigate those risks and make HSCT safer and more
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